Roflumilast for the treatment of diabetes mellitus

US8017633B2 · kind B2 · utility

Assignee

• NYCOMED GMBH · DE

Inventors

• Hans-Peter Kley · Allensbach, DE
• Guido Hanauer · Konstanz, DE
• Daniela Hauser · Singen, DE
• Beate Schmidt · Allensbach, DE
• Dirk Bredenbroeker · Konstanz, DE
• Wilhelm Wurst · Konstanz, DE
• Joerg Kemkowski · Hamburg, DE

Key dates

• Filing date: Mar 3, 2006
• Grant date: Sep 13, 2011
• Expiry date: Mar 9, 2028

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to the use of Roflumilast and/or Roflumilast N-Oxide for the treatment of diabetes mellitus and accompanying disorders thereof. The invention additionally relates to combinations of Roflumilast and/or Roflumilast N-Oxide with other active agents for the treatment of diabetes mellitus.